IDH2 and glioblastoma: Among these, the genomic characterization of GBM with a wildtype IDH gene (GBM, IDH-wildtype) reveals frequent genetic alterations of the growth factor receptor-PI3K-Akt signaling pathway that activate mammalian target of rapamycin (mTOR) signaling [45].